Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Dec;74(11):1757–1761. doi: 10.1038/bjc.1996.626

Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression.

P Sarhanis 1, C Redman 1, C Perrett 1, K Brannigan 1, R N Clayton 1, P Hand 1, C Musgrove 1, V Suarez 1, P Jones 1, A A Fryer 1, W E Farrell 1, R C Strange 1
PMCID: PMC2077203  PMID: 8956789

Abstract

The importance of polymorphism in the glutathione S-transferase GSTM1, GSTT1 and, cytochrome P450, CYP2D6 loci in the pathogenesis of epithelial ovarian cancer has been assessed in two studies; firstly, a case-control study designed to determine the influence of these genes on susceptibility to this cancer, and secondly, the putative role of these genes in the protection of host cell DNA has been studied by comparing p53 expression in patients with different GSTM1, GSTT1 and CYP2D6 genotypes. The frequencies of GSTM1, GSTT1 and CYP2D6 genotypes in 84 cases and 325 controls were not different. Immunohistochemistry was used to detect p53 expression in 63 of these tumours. Expression was found in 23 tumours. Of the patients demonstrating immunopositivity, 20 (87%) were GSTM1 null. The frequency distributions of GSTM1 genotypes in p53-positive and -negative samples were significantly different (P = 0.002) and those for GSTT1 genotypes approached significance (exact P = 0.057). The proportion of patients with both GSTM1 null and GSTT1 null was also significantly greater in the immunopositive (4/22) than in the immunonegative group (1/40) (P = 0.0493). Single-strand conformational polymorphism (SSCP) analysis was used to detect mutations in the 23 tumour samples demonstrating p53 positivity. A shift in electrophoretic mobility of amplified fragments was found in 11 patients (exons 5, 6, 7 and 8) and these exons were sequenced. In eight samples a mutation was found. No SCCP variants were identified in the other 12 immunopositive patients. Sequencing of exons 4-9 of p53 from these tumours resulted in the detection of mutations in two patients (exons 5 and 7). Thus, in 23 patients who demonstrated immunopositivity, p53 mutations were found in nine patients with GSTM1 null (90.0%). In the 13 patients in whom no mutations were identified, 11 were GSTM1 null (84.6%). The data show that overexpression of p53 is associated with the GSTM1 null genotype. We propose the data are compatible with the view that GSTM1 and GSTT1 are critical in the detoxification of the products of oxidative stress produced during the repair of the ovarian epithelium. Thus, failure to detoxify products of this stress may result in damage to various genes in the host cell, including to p53, resulting in persistent expression of mutant protein. In other patients, oxidative stress effects damage to various genes, but not including p53, resulting in overexpression of wild-type p53.

Full text

PDF
1757

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell D. A., Taylor J. A., Paulson D. F., Robertson C. N., Mohler J. L., Lucier G. W. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993 Jul 21;85(14):1159–1164. doi: 10.1093/jnci/85.14.1159. [DOI] [PubMed] [Google Scholar]
  2. Clayton L., Hiley C., Davies S., D'Souza R., Jones P., Strange R., Aber G. Glomerular injury induced by hydrogen peroxide: modifying influence of ACE inhibitors. Free Radic Res Commun. 1992;17(4):271–278. doi: 10.3109/10715769209079519. [DOI] [PubMed] [Google Scholar]
  3. Deakin M., Elder J., Hendrickse C., Peckham D., Baldwin D., Pantin C., Wild N., Leopard P., Bell D. A., Jones P. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis. 1996 Apr;17(4):881–884. doi: 10.1093/carcin/17.4.881. [DOI] [PubMed] [Google Scholar]
  4. Eccles D. M., Russell S. E., Haites N. E., Atkinson R., Bell D. W., Gruber L., Hickey I., Kelly K., Kitchener H., Leonard R. Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. Oncogene. 1992 Oct;7(10):2069–2072. [PubMed] [Google Scholar]
  5. Elexpuru-Camiruaga J., Buxton N., Kandula V., Dias P. S., Campbell D., McIntosh J., Broome J., Jones P., Inskip A., Alldersea J. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Res. 1995 Oct 1;55(19):4237–4239. [PubMed] [Google Scholar]
  6. Godwin A. K., Testa J. R., Hamilton T. C. The biology of ovarian cancer development. Cancer. 1993 Jan 15;71(2 Suppl):530–536. doi: 10.1002/cncr.2820710207. [DOI] [PubMed] [Google Scholar]
  7. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  8. Heagerty A. H., Fitzgerald D., Smith A., Bowers B., Jones P., Fryer A. A., Zhao L., Alldersea J., Strange R. C. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet. 1994 Jan 29;343(8892):266–268. doi: 10.1016/s0140-6736(94)91115-0. [DOI] [PubMed] [Google Scholar]
  9. Heagerty A., Smith A., English J., Lear J., Perkins W., Bowers B., Jones P., Gilford J., Alldersea J., Fryer A. Susceptibility to multiple cutaneous basal cell carcinomas: significant interactions between glutathione S-transferase GSTM1 genotypes, skin type and male gender. Br J Cancer. 1996 Jan;73(1):44–48. doi: 10.1038/bjc.1996.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Nebert D. W. Drug-metabolizing enzymes in ligand-modulated transcription. Biochem Pharmacol. 1994 Jan 13;47(1):25–37. doi: 10.1016/0006-2952(94)90434-0. [DOI] [PubMed] [Google Scholar]
  11. Perrett C. W., Clayton R. N., Pistorello M., Boscaro M., Scanarini M., Bates A. S., Buckley N., Jones P., Fryer A. A., Gilford J. GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: effects on P53, ras and gsp. Carcinogenesis. 1995 Jul;16(7):1643–1645. doi: 10.1093/carcin/16.7.1643. [DOI] [PubMed] [Google Scholar]
  12. Ryberg D., Kure E., Lystad S., Skaug V., Stangeland L., Mercy I., Børresen A. L., Haugen A. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res. 1994 Mar 15;54(6):1551–1555. [PubMed] [Google Scholar]
  13. Shepherd J. H. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol. 1989 Aug;96(8):889–892. doi: 10.1111/j.1471-0528.1989.tb03341.x. [DOI] [PubMed] [Google Scholar]
  14. Sheridan E., Silcocks P., Smith J., Hancock B. W., Goyns M. H. P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. Eur J Cancer. 1994;30A(11):1701–1704. doi: 10.1016/0959-8049(94)00325-y. [DOI] [PubMed] [Google Scholar]
  15. Smith G., Stanley L. A., Sim E., Strange R. C., Wolf C. R. Metabolic polymorphisms and cancer susceptibility. Cancer Surv. 1995;25:27–65. [PubMed] [Google Scholar]
  16. Spragg R. G. DNA strand break formation following exposure of bovine pulmonary artery and aortic endothelial cells to reactive oxygen products. Am J Respir Cell Mol Biol. 1991 Jan;4(1):4–10. doi: 10.1165/ajrcmb/4.1.4. [DOI] [PubMed] [Google Scholar]
  17. Wolf C. R., Smith C. A., Gough A. C., Moss J. E., Vallis K. A., Howard G., Carey F. J., Mills K., McNee W., Carmichael J. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis. 1992 Jun;13(6):1035–1038. doi: 10.1093/carcin/13.6.1035. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES